Suppr超能文献

肾细胞癌局部复发的治疗

Therapy of local recurrence of renal cell carcinoma.

作者信息

Wiesner Christoph, Jakse Gerhard, Rohde Detlef

机构信息

Department of Urology, Medical Faculty, University of Aachen, Aachen, Germany.

出版信息

Oncol Rep. 2002 Jan-Feb;9(1):189-92.

Abstract

Local recurrence (LR) of renal cell carcinoma (RCC) after nephrectomy is a rare event with a poor prognosis. The clinical outcome of 15 patients with LR after tumor nephrectomy was analyzed retrospectively. Within a mean follow-up of 28 months (1-110 months) the mean time to recurrence (TTLR) was 23 months. Mean time to further tumor progression (TTP) after surgery was 22.2 months (11-32 months), after surgery and adjunctive therapy 6.8 months (3-15 months+) and after chemoimmunotherapy alone 3.6 months (3-6 months). Tumor specific survival (TSS) rate was 47% at 1 year and 33% at 3 years. Mean TSS after surgery was 62.2 months (38-110 months), after resection and adjunctive treatment 26 months (8-74 months) and after chemoimmunotherapy 9.2 months (7-15 months). In conclusion, surgery is recommended for treatment of LR. Additional benefit is not confirmed for any adjuctive therapy.

摘要

肾切除术后肾细胞癌(RCC)的局部复发(LR)是一种罕见事件,预后较差。对15例肿瘤肾切除术后发生LR的患者的临床结局进行了回顾性分析。在平均28个月(1 - 110个月)的随访期内,平均复发时间(TTLR)为23个月。术后至肿瘤进一步进展(TTP)的平均时间为22.2个月(11 - 32个月),术后联合辅助治疗后为6.8个月(3 - 15个月以上),单纯化疗免疫治疗后为3.6个月(3 - 6个月)。1年时的肿瘤特异性生存率(TSS)为47%,3年时为33%。术后平均TSS为62.2个月(38 - 110个月),切除及辅助治疗后为26个月(8 - 74个月),化疗免疫治疗后为9.2个月(7 - 15个月)。总之,建议手术治疗LR。未证实任何辅助治疗有额外益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验